SCHEMBL4461353

SCHEMBL4461353

O=C(Nc1ccc(-c2c[nH]c(COc3ccccc3)n2)cc1)c1ccc(F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.62
KMT2A Q03164 7/20 0.62
RXFP1 Q9HBX9 3/20 0.62
LMNA P02545 2/20 0.62
PTPN1 P18031 3/20 0.52
PTPN6 P29350 1/20 0.52
PTPN11 Q06124 1/20 0.52
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
POLB P06746 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.47
PTPN2 P17706 1/20 0.47
MAPT P10636 2/20 0.47
CXCR1 P25024 1/20 0.47
CXCR2 P25025 1/20 0.47
MAPK1 P28482 1/20 0.47
FZD7 O75084 1/20 0.46
BCL2L1 Q07817 1/20 0.45
MCL1 Q07820 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4684267 1.00 MEN1 (0.62) MEN1KMT2ARXFP1LMNAPTPN1
Trifluoroacetic Acid SCHEMBL4456741 0.95 MEN1 (0.57) MEN1KMT2ARXFP1LMNAPTPN1
SCHEMBL4681552 0.81 NR4A2 (0.49) NPC1RAB9ASMN1; SMN2MCL1
SCHEMBL4460188 0.80 NPC1 (0.45) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL4685016 0.80 GAA (0.47) MEN1KMT2ALMNARAB9ASMN1; SMN2
SCHEMBL3269527 0.80 ALOX5 (0.50) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL4457369 0.79 MEN1 (0.48) MEN1KMT2ARXFP1LMNAPOLB
SCHEMBL3275341 0.79 MCL1 (0.43) MEN1KMT2ALMNANPC1RAB9A
SCHEMBL4681091 0.78 LTA4H (0.54) MEN1KMT2ALMNANPC1RAB9A
Hydrochloric Acid SCHEMBL4453553 0.78 LTA4H (0.53) MEN1KMT2ALMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US claimed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP claimed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US claimed
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed
EP-1638943-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-03-29 EP disclosed
WO-2004106307-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 MEN1 280/4885KMT2A 1755/4885RXFP1 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.